Literature DB >> 1787936

Tissue plasminogen activator modifies healing of glaucoma filtering surgery in rabbits.

S Fourman1, L Wiley.   

Abstract

The healing response after glaucoma filtering surgery was analyzed immunohistochemically in rabbit eyes that had been treated with tissue plasminogen activator immediately after surgery and in the fellow eyes that had not been so treated. In the untreated eyes, at 1 day after surgery, fibronectin-like immunoreactivity was seen in the scleral fistula tract but not in the subconjunctival space of the filtering bleb. At 3 days immunoreactivity for fibronectin, collagen III, and collagen I could be seen in the bleb and fistula tract. By 14 days staining for collagen I and collagen III filled the surgical site, but fibronectin could only be seen in the fistula tract. In the eyes treated with tissue plasminogen activator immediately after surgery, the deposition of fibronectin and collagen III in the subconjunctival space and fistula tract was apparently delayed and diminished. This delayed and reduced deposition was correlated with the delayed clinical failure of surgery in these eyes. These results suggest that alteration of the biochemical changes in the extracellular matrix occurring after filtering surgery may influence the success of this surgery.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1787936

Source DB:  PubMed          Journal:  Ophthalmic Surg        ISSN: 0022-023X


  2 in total

1.  Recombinant tissue plasminogen activator in cases with fibrin formation after cataract surgery: a prospective randomised multicentre study.

Authors:  A Heiligenhaus; B Steinmetz; R Lapuente; P Krallmann; C Althaus; W K Steinkamp; B Dick
Journal:  Br J Ophthalmol       Date:  1998-07       Impact factor: 4.638

2.  Antifibrotic effects of tocotrienols on human Tenon's fibroblasts.

Authors:  Christoph Tappeiner; Alexander Meyenberg; David Goldblum; Daniel Mojon; Jean-Marc Zingg; Kalanithi Nesaretnam; Monika Kilchenmann; Beatrice E Frueh
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-08-14       Impact factor: 3.117

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.